Related Experiment Video

Updated: Jun 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Castration resistant prostate cancer 2011]

K Miller1

  • 1Urologische Klinik Charité, Berlin, Germany. kurt.miller@charite.de

Aktuelle Urologie
|March 26, 2011
PubMed

Insights

Castration-resistant prostate cancer treatment is evolving. New drugs targeting androgen receptor signaling demonstrate that even advanced prostate cancer remains hormone-driven, necessitating updated terminology and therapeutic strategies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Prostate cancer treatment paradigms are shifting.
  • The term "hormone refractory" is being replaced by "castration-resistant prostate cancer".

Purpose of the Study:

  • To provide an overview of current drug development in castration-resistant prostate cancer.
  • To discuss therapeutic consequences and future trends in prostate cancer treatment.

Main Methods:

  • Review of recent advancements in prostate cancer drug development.
  • Analysis of clinical data for novel therapeutic agents.

Main Results:

  • New drugs, such as CYP-17 inhibitors (e.g., abiraterone), are effective in castration-resistant prostate cancer.
  • Androgen receptor signaling remains a key driver of progression even in advanced stages.

Conclusions:

  • Castration-resistant prostate cancer is still driven by androgen receptor signaling.
  • Updated understanding necessitates changes in terminology and treatment approaches.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...